Orchid Pharma

Who are the top shareholders of the Orchid Pharma?

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited with a 69.84% stake, mutual funds at 18.79% (led by Quant Small Cap Fund at 6.83%), Foreign Institutional Investors at 2.69%, and individual investors holding 5.11%. There are no pledged promoter holdings reported.

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited, which holds the highest promoter stake at 69.84%. Additionally, mutual funds collectively hold 18.79% of the shares, with the Quant Mutual Fund - Quant Small Cap Fund being the largest public shareholder at 6.83%. Foreign Institutional Investors (FIIs) have a stake of 2.69%, and individual investors hold 5.11% of the shares. There are no pledged promoter holdings reported.

how big is Orchid Pharma?

As of Jun 06, Orchid Pharma Ltd has a market capitalization of 3,636.56 Cr, with recent net sales of 921.93 Cr and a net profit of 99.66 Cr. Shareholder's funds are 1,169.47 Cr, and total assets amount to 1,553.87 Cr.

Market Cap: As of Jun 06, Orchid Pharma Ltd has a market capitalization of 3,636.56 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 921.93 Cr and a net profit of 99.66 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar 24. Shareholder's funds are reported at 1,169.47 Cr, while total assets amount to 1,553.87 Cr.

Has Orchid Pharma declared dividend?

Orchid Pharma has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 13, 2012. However, the dividend yield is 0%, and total returns have shown significant volatility, with notable gains over the 5-year period despite recent declines.

Orchid Pharma Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3<BR>- Ex-date: 13 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -59.45%, the dividend return was 0%, resulting in a total return of -59.45%.<BR><BR>For the 1-year period, the price return was -32.95%, the dividend return was 0%, leading to a total return of -32.95%.<BR><BR>Over the 2-year period, the price return was 72.37%, with a dividend return of 0%, resulting in a total return of 72.37%.<BR><BR>In the 3-year period, the price return was 137.39%, the dividend return was 0%, culminating in a total return of 137.39%.<BR><BR>For the 4-year period, the price return was -49.4%, with a dividend return of 0%, leading to a total return of -49.4%.<BR><BR>In the 5-year period, the price return was 13462.86%, with a dividend return of 0%, resulting in a total return of 13462.86%.<BR><BR>Overall, while Orchid Pharma has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with substantial gains over longer periods, particularly in the 5-year timeframe.

Who are the peers of the Orchid Pharma?

Orchid Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Senores Pharma, SMS Pharma, and Zota Health Care. Orchid Pharma has below-average management risk, growth, and capital structure, with a 1-year return of -31.39%, the lowest among its peers.

Peers: The peers of Orchid Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Senores Pharma., SMS Pharma, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is present at IOL Chemicals and Novartis India, while Below Average management risk is noted for Orchid Pharma and Senores Pharma. Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Senores Pharma, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Orchid Pharma, IOL Chemicals, SMS Pharma, and Zota Health Care. Excellent capital structure is found at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., IOL Chemicals, and Novartis India, while Good capital structure is seen at Torrent Pharma and Senores Pharma, and Below Average capital structure is noted for Orchid Pharma and SMS Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Orchid Pharma has the lowest at -31.39%. Orchid Pharma's return is significantly lower than all peers. Additionally, the six-month return is negative for Orchid Pharma, Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and Zota Health Care.

Who are in the management team of Orchid Pharma?

As of March 2023, the management team of Orchid Pharma includes Tanu Singla, Dharam Vir, Mudit Tandon, Manoj Goyal (all Independent Directors), Manish Dhanuka (Managing Director), Mridul Dhanuka (Whole-time Director), Ram Gopal Agarwal (Chairman), and Marina Peter (Company Secretary & Compliance Officer).

As of March 2023, the management team of Orchid Pharma includes the following individuals:<BR><BR>1. Tanu Singla - Independent Director<BR>2. Dharam Vir - Independent Director<BR>3. Mudit Tandon - Independent Director<BR>4. Manoj Goyal - Independent Director<BR>5. Manish Dhanuka - Managing Director<BR>6. Mridul Dhanuka - Whole-time Director<BR>7. Ram Gopal Agarwal - Chairman (Non-Executive)<BR>8. Marina Peter - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and management of the company.

What does Orchid Pharma do?

Orchid Pharma Ltd is a leading Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 3,789 Cr and reported net sales of 2,375 Cr and net profit of 223 Cr for March 2025. The company has a P/E ratio of 38.00 and a return on equity of 7.86%.

Overview:<BR>Orchid Pharma Ltd is a leading pharmaceutical company in India, operating in the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History:<BR>Orchid Pharma was incorporated in an unspecified year and has undergone various status changes. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,375 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 223 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: INR 3,789 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.00<BR>- Return on Equity: 7.86%<BR>- Price to Book: 2.96<BR><BR>Contact Details:<BR>- Address: Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road Chennai Tamil Nadu : 600034<BR>- Tel: 91-44-28211000/28230000<BR>- Email: corporate@orchidpharma.com<BR>- Website: http://www.orchidpharma.com

Is Orchid Pharma overvalued or undervalued?

As of July 21, 2025, Orchid Pharma is considered overvalued with a PE ratio of 36.74 and an EV to EBITDA of 31.21, significantly higher than its peers, and has underperformed with a year-to-date return of -60.27% compared to the Sensex's gain of 5.20%.

As of 21 July 2025, Orchid Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. Despite this change, the company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.74, while the EV to EBITDA ratio is 31.21, both of which are significantly higher than many of its peers. Additionally, the PEG ratio of 4.17 suggests that the stock may be priced too high relative to its growth prospects.<BR><BR>In comparison to its peers, Sun Pharma has a PE of 35.52 and an EV to EBITDA of 25.11, while Cipla shows a more attractive valuation with a PE of 22.6 and an EV to EBITDA of 15.65. These comparisons highlight that Orchid Pharma's valuation is not justified when considering its earnings and growth potential. Furthermore, the company's year-to-date return of -60.27% starkly contrasts with the Sensex's gain of 5.20%, reinforcing the notion that Orchid Pharma is currently overvalued.

When is the next results date for Orchid Pharma?

The next results date for Orchid Pharma is 12 August 2025.

The next results date for Orchid Pharma is scheduled for 12 August 2025.

How has been the historical performance of Orchid Pharma?

Orchid Pharma has shown significant financial improvement from March 2023 to March 2025, with net sales increasing from 665.90 Cr to 921.93 Cr, and consolidated net profit rising from 46.32 Cr to 99.66 Cr, indicating strong recovery and growth. Total assets and liabilities grew in tandem, while cash flow from operations improved markedly.

Answer:<BR>The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.

Is Orchid Pharma technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by daily moving averages and a bullish RSI on the monthly chart, though mixed signals from the MACD and Bollinger Bands indicate divergence between short-term and long-term trends.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is also mildly bullish, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The RSI shows a bullish signal on the monthly chart, but no signal on the weekly, indicating potential strength in the longer term. Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the mixed outlook. Overall, the strength of the bullish stance is moderate, with key indicators showing divergence between short-term and long-term trends.

Are Orchid Pharma Ltd latest results good or bad?

Orchid Pharma Ltd's latest results are concerning, showing a consolidated net loss of ₹12.61 crore for Q3 FY26, a 160.68% decline year-on-year, and a significant drop in profitability with operating margins at just 0.76%. Overall, the financial performance indicates ongoing structural challenges, marking the results as bad.

Orchid Pharma Ltd's latest results indicate a troubling financial situation. For Q3 FY26, the company reported a consolidated net loss of ₹12.61 crore, which is a significant decline of 160.68% year-on-year. This marks the second consecutive quarter of losses, following a loss of ₹5.72 crore in the previous quarter.<BR><BR>Net sales for the quarter were ₹207.27 crore, reflecting a 4.63% decrease compared to the same period last year, although there was a slight sequential recovery of 7.11% from the previous quarter. However, this modest revenue growth is overshadowed by the severe drop in profitability, with operating margins collapsing to just 0.76%, down from 12.13% a year ago.<BR><BR>The company has faced a dramatic erosion in profitability over the nine-month period ending December 2025, with consolidated profit plummeting 95.23% to ₹3.69 crore compared to ₹77.37 crore in the same period of FY25. This suggests deep operational challenges that have significantly impacted Orchid Pharma's ability to generate profitable sales.<BR><BR>Overall, the financial performance points to a company in distress, with critical red flags such as negative operating margins, weak return metrics, and a substantial decline in profitability. The market has reacted negatively, with the stock underperforming the broader market significantly. Given these factors, the latest results can be characterized as bad, reflecting ongoing structural issues rather than temporary setbacks.

Should I buy, sell or hold Orchid Pharma Ltd?

Why is Orchid Pharma Ltd falling/rising?

As of 17-Mar, Orchid Pharma Ltd's stock price is rising to Rs 525.00, up 4.03%, driven by a trend reversal and increased investor participation despite weak long-term fundamentals. The stock's recent performance suggests a potential shift in sentiment, aided by high institutional holdings.

As of 17-Mar, Orchid Pharma Ltd's stock price is rising, currently at Rs 525.00, reflecting an increase of Rs 20.35 or 4.03%. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 3.75% today and has shown a trend reversal after two consecutive days of decline. Additionally, the stock reached an intraday high of Rs 536.15, marking a 6.24% increase during the trading session.<BR><BR>Investor participation has also increased, with a delivery volume of 1.52 lakh shares on March 16, which is a significant rise of 59.33% compared to the 5-day average. This heightened interest suggests a growing confidence among investors, despite the stock's overall weak long-term fundamentals, as indicated by its average Return on Equity (ROE) of 4.62% and negative results over the last five quarters.<BR><BR>While the stock has faced challenges, including a -34.80% return over the past year and a -20.89% decline over the past month, the recent performance indicates a potential shift in sentiment. The presence of high institutional holdings at 20.56% may also contribute to the stock's resilience, as institutional investors typically have more resources to analyze the company's fundamentals. Overall, the combination of today's positive performance metrics and increased investor activity is driving the stock's rise.

Why is Orchid Pharma Ltd falling/rising?

As of 18-Mar, Orchid Pharma Ltd's stock price is rising to Rs 538.50, reflecting a 1.95% increase. Despite recent short-term gains, the stock has a troubling long-term outlook with a -35.43% return over the past year and ongoing negative financial performance.

As of 18-Mar, Orchid Pharma Ltd's stock price is rising, currently at Rs 538.50, reflecting a change of Rs 10.3, or 1.95%. This upward movement can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 1.9% today and has experienced consecutive gains over the last two days, accumulating a total return of 6.94% during this period. Additionally, the stock reached an intraday high of Rs 544.4, indicating positive trading momentum.<BR><BR>However, it is important to note that despite this recent rise, the stock has faced significant challenges in the longer term. Over the past year, it has generated a return of -35.43%, and its performance over the last month shows a decline of -19.43%. The company has also reported negative results for the last five consecutive quarters, with a substantial drop in profits, which raises concerns about its long-term viability.<BR><BR>Moreover, while there is a high institutional holding of 20.56%, indicating some level of confidence from larger investors, the company's weak fundamentals, such as a low return on equity (ROE) of 4.62% and a poor EBIT to Interest ratio of 1.92, suggest that the stock may still be facing underlying issues despite its short-term gains. Thus, while the stock is currently rising, its long-term outlook remains precarious.

Why is Orchid Pharma Ltd falling/rising?

As of 19-Mar, Orchid Pharma Ltd's stock price is falling to Rs 517.50, down 3.9%, due to weak financial performance, declining investor interest, and underperformance compared to its sector. The stock is also trading below its moving averages, indicating a bearish trend.

As of 19-Mar, Orchid Pharma Ltd's stock price is falling, currently at Rs 517.50, reflecting a decrease of Rs 21.0 or 3.9%. This decline is attributed to several factors. The stock has underperformed its sector, showing a performance today that is 1.75% lower than the sector average. Additionally, the stock has experienced a trend reversal, having fallen after two consecutive days of gains. It reached an intraday low of Rs 513.85, marking a drop of 4.58%.<BR><BR>The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Furthermore, the pharmaceuticals and drugs sector has also seen a decline of 2.13%, contributing to the negative sentiment surrounding Orchid Pharma.<BR><BR>Investor participation has decreased significantly, with delivery volume on 18 March dropping by 64.92% compared to the 5-day average, suggesting reduced interest from investors. The company's fundamentals are weak, as evidenced by a low Return on Equity (ROE) of 4.62% and negative results over the last five consecutive quarters, including a staggering 95.23% decline in Profit After Tax (PAT) for the first nine months.<BR><BR>Overall, the combination of poor financial performance, declining investor interest, and underperformance relative to both the sector and broader market indices has led to the stock's current downward trajectory.

Why is Orchid Pharma Ltd falling/rising?

As of 20-Mar, Orchid Pharma Ltd's stock price is rising to 525.00, reflecting a short-term increase despite significant long-term declines and weak financial performance. The stock's positive movement today contrasts with a 21.45% drop over the past month and ongoing negative results, indicating a concerning outlook.

As of 20-Mar, Orchid Pharma Ltd's stock price is rising, currently at 525.00, with a change of 8.55 (1.66%) upward. This increase can be attributed to a few factors. Firstly, the stock has shown a positive performance today, reaching an intraday high of Rs 540.05, which reflects a rise of 4.57%. Additionally, the stock's performance is reported to be inline with its sector, suggesting that it is not underperforming relative to its peers.<BR><BR>However, it is important to note that despite the short-term rise, the stock has experienced significant declines over longer periods. For instance, it has fallen by 21.45% over the past month and 30.84% year-to-date. The company has also reported negative results for the last five consecutive quarters, with a substantial decrease in profits, indicating weak long-term fundamental strength. The average Return on Equity (ROE) is low at 4.62%, and the company's ability to service its debt is poor, as evidenced by an EBIT to Interest ratio of 1.92.<BR><BR>Moreover, there has been a notable decline in investor participation, with delivery volume falling by 63.1% against the 5-day average. This could indicate a lack of confidence among investors, despite the current rise in stock price. High institutional holdings at 20.56% may provide some support, as these investors typically have better resources to analyze the company's fundamentals.<BR><BR>In summary, while Orchid Pharma Ltd is experiencing a short-term rise in stock price, the long-term outlook remains concerning due to weak financial performance and declining investor participation.

Why is Orchid Pharma Ltd falling/rising?

As of 23-Mar, Orchid Pharma Ltd's stock price has declined to Rs 510.00, down 4.92%, with a year-to-date drop of 32.82%. Weak financial fundamentals, decreased investor interest, and negative sector trends are driving this decline.

As of 23-Mar, Orchid Pharma Ltd is experiencing a decline in its stock price, currently at Rs 510.00, which represents a decrease of Rs 26.4 or 4.92%. This downward movement is reflected in several key performance indicators. Over the past month, the stock has fallen by 23.34%, significantly underperforming the benchmark Sensex, which declined by only 12.72% during the same period. Year-to-date, the stock has dropped by 32.82%, while the Sensex has decreased by 14.70%.<BR><BR>The stock's performance today indicates a struggle, as it is trading close to its 52-week low, just 4.16% above Rs 488.8. The stock touched an intraday low of Rs 504.75, marking a 5.9% decline. Additionally, Orchid Pharma has underperformed its sector by 1.35% today, and it is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.<BR><BR>Investor participation has also waned, with delivery volume on March 20 falling by 52.75% compared to the 5-day average, indicating decreased interest from investors. The overall sector, Pharmaceuticals & Drugs, has seen a decline of 3.62%, contributing to the negative sentiment surrounding Orchid Pharma.<BR><BR>The company's financial fundamentals are weak, with a low return on equity (ROE) of 4.62% and a poor EBIT to Interest ratio of 1.92, suggesting challenges in servicing its debt. Furthermore, Orchid Pharma has reported negative results for the last five consecutive quarters, with a significant drop in profit after tax (PAT) of 95.23% and a return on capital employed (ROCE) of only 2.3. This poor performance has led to a perception of the stock being overvalued despite trading at a discount compared to its peers.<BR><BR>In summary, the combination of weak financial performance, declining investor interest, and negative sector trends are contributing to the falling stock price of Orchid Pharma Ltd.

Why is Orchid Pharma Ltd falling/rising?

As of 24-Mar, Orchid Pharma Ltd's stock price is at 513.30, showing a slight increase of 0.45%. However, the stock has faced significant declines over various periods, including a 32.38% drop year-to-date and a 38.18% fall over the last year, indicating a persistent downward trend despite today's minor rise.

As of 24-Mar, Orchid Pharma Ltd's stock price is currently at 513.30, reflecting a change of 2.3 (0.45%) increase. However, despite this slight rise, the stock has been experiencing significant downward pressure over various time frames. Over the past week, the stock has declined by 2.82%, and it has seen a substantial drop of 20.52% over the past month. Year-to-date, the stock is down 32.38%, and it has fallen 38.18% over the last year.<BR><BR>The stock is trading close to its 52-week low, just 4.77% above the low of Rs 488.8, indicating a lack of upward momentum. Additionally, Orchid Pharma has underperformed its sector by 0.67% today and is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend.<BR><BR>Investor participation has also declined, with delivery volume dropping by 30.27% compared to the 5-day average, indicating reduced interest from investors. Furthermore, the company has reported negative results for the last five consecutive quarters, with a significant decline in profits, as evidenced by a 95.23% decrease in PAT over the last nine months and a staggering 346.1% fall in PBT.<BR><BR>The company's long-term fundamentals are weak, highlighted by an average Return on Equity (ROE) of only 4.62% and a poor EBIT to Interest ratio of 1.92, suggesting challenges in servicing its debt. The stock's performance has been below par both in the long term and near term, contributing to its overall decline. Thus, while there is a minor increase in the stock price today, the broader context indicates a persistent downward trend for Orchid Pharma Ltd.

Why is Orchid Pharma Ltd falling/rising?

As of 25-Mar, Orchid Pharma Ltd's stock price is rising to Rs 530.65, up 3.38% today. Despite this short-term gain, the long-term outlook is weak due to a -32.74% return over the past year and poor financial fundamentals.

As of 25-Mar, Orchid Pharma Ltd's stock price is rising, currently at Rs 530.65, reflecting an increase of Rs 17.35 or 3.38%. This upward movement can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 1.49% today and has shown consecutive gains over the last two days, accumulating a total return of 3.85% during this period. Additionally, the stock reached an intraday high of Rs 547.95, marking a significant increase of 6.75%.<BR><BR>However, it is important to note that despite the recent rise, the stock has been underperforming in the longer term. Over the past year, it has generated a return of -32.74%, and its performance over the last month shows a decline of 15.50%. The company's fundamentals appear weak, with a low average Return on Equity (ROE) of 4.62% and negative results reported for the last five consecutive quarters. The company's ability to service its debt is also concerning, as indicated by a poor EBIT to Interest ratio of 1.92.<BR><BR>In summary, while Orchid Pharma Ltd is experiencing a short-term rise in stock price, the long-term outlook remains weak due to poor financial performance and fundamentals.

Which are the latest news on Orchid Pharma?